starpharma | home
home
about starpharma
technology
product pipeline
news room
investor relations
careers contact us
site search

 
 

News & Announcements
Appendix 4C - Quarterly Cash Flow Report
28/04/2008

Change of Director`s Interest Notice R Dobinson
24/04/2008

Opes Prime overhang cleared
24/04/2008

Dr John Raff Change of Director`s Interest Notice
23/04/2008

First commercial product launch DNT Priostar dendrimers
22/04/2008

Excellence in Biotech Investment CEO Presentation
21/04/2008

SPL7013 Inhibits Clinically Relevant Strains of HPV
21/04/2008

Dendrimer SPL7013 Potential Application for Arthritis
14/04/2008

Standard & Poor's Stock Report
Click here to view

Merriman Curhan Ford & Co. Equity Research on Starpharma
Click here to view

Analyst Reports
Bioshares issue 244
10/12/2007

 

starpharma - leading the world in nano-medicine.

Starpharma Holdings Limited is a world leader in the development of dendrimer nanotechnology products for pharmaceutical, life-science and other applications.

Starpharma's lead product is VivaGel™, a gel-based formulation of a nano-pharmaceutical that is being developed as a vaginal microbicide to protect women from the sexually transmitted infections, HIV and genital herpes.

VivaGel™ has been successfully tested in a Phase I clinical trial, with new trials currently underway in Australia, the United States and Kenya. VivaGel™ has been granted Fast Track status by the US Food and Drug Administration (FDA) which will accelerate the clinical and regulatory process. In addition, VivaGel™ has been awarded US$20.3 million by the NIH to accelerate its development for HIV. The NIH has provided additional funding support to develop VivaGel™ against genital herpes.

In October 2006 Starpharma acquired US-based Dendritic Nanotechnologies Inc (DNT) expanding the company's potential products to include drug delivery and industrial specialty chemical appliances. Many of these applications have near-term cash-flow opportunities.